Acrivon Therapeutics (ACRV) CFO awarded 46,167 RSUs, holdings rise to 67,150 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Levy Adam D. reported acquisition or exercise transactions in this Form 4 filing.

Acrivon Therapeutics, Inc. reported that its Chief Financial Officer, Adam D. Levy, received an equity compensation grant in the form of restricted stock units. He was awarded 46,167 RSUs of common stock at no cash cost, increasing his directly held shares to 67,150 after the grant.

Each RSU represents a contingent right to receive one share of common stock. According to the vesting schedule, 16.67% of the RSUs will vest on November 18, 2026, with the remaining units vesting in 10 substantially equal quarterly installments, subject to his continuous service with the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Levy Adam D.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	46,167	$0.00	--

Holdings After Transaction: Common Stock — 67,150 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSU grant size: 46,167 shares Post-transaction holdings: 67,150 shares Grant price: $0.0000 per share +2 more

5 metrics

RSU grant size 46,167 shares Restricted stock units awarded to CFO on May 18, 2026

Post-transaction holdings 67,150 shares CFO direct common stock holdings after grant

Grant price $0.0000 per share Form 4 transaction price for RSU award

Initial vesting tranche 16.67% of RSUs Vests on November 18, 2026, subject to continuous service

Remaining vesting schedule 10 quarterly installments After November 18, 2026, substantially equal vesting

Key Terms

restricted stock units ("RSUs"), contingent right, continuous service, substantially equal quarterly installments

4 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

continuous service financial

"in each case subject to the Reporting Person's continuous service through each such vesting date."

substantially equal quarterly installments financial

"the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

05/20/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levy Adam D.

(Last)

(First)

(Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/18/2026		A⁽¹⁾		46,167	A	$0	67,150	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report for its CFO?

Acrivon Therapeutics reported that CFO Adam D. Levy received a grant of 46,167 restricted stock units. These RSUs are equity compensation, cost him no cash, and increase his directly held common shares to 67,150 after the transaction.

How many Acrivon Therapeutics (ACRV) shares does the CFO hold after this Form 4?

After the reported grant, CFO Adam D. Levy holds 67,150 shares of Acrivon Therapeutics common stock. This total reflects the addition of 46,167 restricted stock units awarded as compensation, which convert into shares as they vest over time.

What are the vesting terms of the CFO’s Acrivon Therapeutics (ACRV) RSU grant?

The 46,167 RSUs granted to the CFO vest over several years. 16.67% vest on November 18, 2026, and the remaining units vest in 10 substantially equal quarterly installments, each contingent on his continuous service with Acrivon Therapeutics.

Does the Acrivon Therapeutics (ACRV) CFO RSU grant involve an open-market stock purchase?

No, the CFO’s transaction is a grant of restricted stock units classified as an award acquisition. The Form 4 shows a price of $0.0000 per share, indicating compensation rather than an open-market share purchase on an exchange.

What does each RSU in the Acrivon Therapeutics (ACRV) grant represent?

Each restricted stock unit in the CFO’s grant represents a contingent right to receive one share of Acrivon Therapeutics common stock. The rights convert into actual shares only as the RSUs vest according to the specified schedule and service conditions.